Tumor RNA Transfected Dendritic Cell Vaccines

US Department of Veterans Affairs

Overview

The purpose of this study is to use dendritic cells transfected with amplified RNA from autologous tumor cells to develop a vaccine strategy for the treatment of prostate cancer in patients with disseminated disease.

The specific aims are: 1) to evaluate, in a phase I clinical trial, the safety of vaccinating patients with dendritic cells transfected with RNA from autologous cancer cells; 2) to analyze the T cell responses induced by the treatment; and 3) to improve the efficacy of the treatment by developing methods to increase the induction of CD4+T cell responses.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Conditions

Prostate Cancer

Interventions

Tumor RNA transfected dendritic cellsBIOLOGICAL

Eligibility

Sex: MALEMin age: 10 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a histologically confirmed diagnosis of metastatic prostate cancer stages D1 - D3 are eligible for this study. * They must not have a history of autoimmune disease, serious intercurrent chronic or acute illness, pulmonary disease, active hepatitis, serologic evidence for HIV, or be receiving corticosteroid or immunosuppressive therapy. Exclusion Criteria: * Patients will be excluded from the study if they have received chemotherapy or other forms of immunotherapy in the 6 weeks prior to study entry.

Locations (1)

Durham VA Medical Center

Durham, North Carolina, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.